Why the study?
NVAF patients with creatinine clearance ≥ 50 mL/min often receive less than the recommended rivaroxaban dose due to bleeding concerns, but the effect of under-dosing on safety and effectiveness remains unclear.
Does under-dosing rivaroxaban (10 mg vs 15 mg) increase thromboembolic events or reduce bleeding in Japanese patients with NVAF and CrCl ≥ 50 mL/min?
Population
6521 NVAF patients with creatinine clearance ≥ 50 mL/min who completed 1-year follow-up in Japan
Comparison
Rivaroxaban 10 mg od (under-dose) vs 15 mg od (recommended dose)
Design
Sub-analysis of a prospective single-arm observational study
Follow-up
1-year
Authors
Loading...
Under-dosing may raise ischemic risk despite fewer bleeds; leaves open optimal real-world dosing strategies in Japanese NVAF.
Does under-dosing rivaroxaban (10 mg vs 15 mg) increase thromboembolic events or reduce bleeding in Japanese patients with NVAF and CrCl ≥ 50 mL/min?
Under-dosing rivaroxaban in Japanese NVAF patients with CrCl ≥ 50 mL/min increases thromboembolic risk without significantly reducing major bleeding, supporting adherence to recommended dosing.
Ikeda et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: